FBLG - CIK 0001958777
The table below shows FibroBiologics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $2.95M | $2.79M | $2.04M | $1.78M | $1.21M | $975.00K |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.12M |
| $2.25M |
| $2.45M |
| $2.75M |
| $2.14M |
| $2.25M |
| Operating income | -$5.07M | -$5.04M | -$4.49M | -$4.53M | -$3.35M | -$3.22M |
| Income tax | $0.00 | - | - | $0.00 | - | - |
| Net income | -$5.00M | -$5.78M | -$4.66M | -$4.97M | -$500.00K | $898.00K |
| EPS (diluted) | -$1.33 | -$0.13 | -$0.12 | -$2.71 | -$0.01 | $0.03 |